Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov-Dec;26(6):537-542.
doi: 10.4103/ijem.ijem_350_22. Epub 2023 Feb 7.

Effect of Hydroxychloroquine on Glycemic Variability in Type 2 Diabetes Patients Uncontrolled on Glimepiride and Metformin Therapy

Rajesh Rajput  1 , Suyasha Saini  1 , Siddhant Rajput  1 , Parankush Upadhyay  1
Affiliations

Effect of Hydroxychloroquine on Glycemic Variability in Type 2 Diabetes Patients Uncontrolled on Glimepiride and Metformin Therapy

Rajesh Rajput et al. Indian J Endocrinol Metab. 2022 Nov-Dec.

Abstract

Background and aims: No study to date has assessed the effect of hydroxychloroquine on various parameters of glycaemic variability. To assess the effect of hydroxychloroquine on glycaemic variability in type 2 diabetes patients uncontrolled on glimepiride and metformin.

Methods: A total of 30 T2DM patients aged 18-65 years uncontrolled on glimepiride and metformin therapy with HbA1c 7.5-10% (58-86 mmol/mol) were given adjunctive hydroxychloroquine 400 mg during the 12-week study period. The glycaemic variability parameters such as standard deviation of 24 hours of blood glucose, mean of daily differences (MODD) and mean amplitude of glycaemic excursion (MAGE) were assessed by continuous glucose monitoring system (CGMS) data at baseline and at 12 weeks after the addition of hydroxychloroquine 400 mg. Efficacy was assessed by change in fasting, postprandial plasma glucose and HbA1c from baseline to 12 weeks of addition of 400 mg hydroxychloroquine.

Results: There was a significant reduction in all parameters of glycaemic variability including MAGE, MODD, standard deviation of 24-hour blood glucose and average blood glucose as well as a significant reduction in fasting, postprandial blood glucose and glycated haemoglobin post 12 weeks of adjunctive treatment with hydroxychloroquine. At the end of 12 weeks of adjunctive treatment with hydroxychloroquine, there was a significant improvement in the percentage of time spent in the target glucose range of 3.9-8.3 mmol/L (70-150 mg/dL).

Conclusion: The addition of hydroxychloroquine in uncontrolled diabetes significantly reduces all glycaemic parameters including all parameters of glycaemic variability and hence can be an effective add-on to patients uncontrolled on glimepiride and metformin therapy.

Keywords: Glycaemic variability; T2DM; hydroxychloroquine.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Average blood glucose throughout the day between pre- and post hydroxychloroquine
Figure 2
Figure 2
Box graph showing fasting, postprandial, average blood glucose and MAGE pre- and post hydroxychloroquine
See this image and copyright information in PMC

References

    1. Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045:Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. - PubMed
    1. ACCORD Study Group. Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364:818–28. - PMC - PubMed
    1. Brownlee M, Hirsch IB. Glycemic variability:A hemoglobin A1c-independent risk factor for diabetic complications. JAMA. 2006;295:1707–8. - PubMed
    1. Kovatchev BP. Metrics for glycemic control-from HbA1c to continuous glucose monitoring. Nat Rev Endocrinol. 2017;13:425–36. - PubMed
    1. Kaze AD, Santhanam P, Erqou S, Ahima RS, Echouffo-Tcheugui JB. Long-term variability of glycemic markers and risk of all-cause mortality in type 2 diabetes:The look ahead study. BMJ Open Diabetes Res Care. 2020;8:e001753. - PMC - PubMed

LinkOut - more resources